WO2000062757A1 - Composition contenant des antagonistes opioides et atomiseur - Google Patents

Composition contenant des antagonistes opioides et atomiseur Download PDF

Info

Publication number
WO2000062757A1
WO2000062757A1 PCT/GB2000/001509 GB0001509W WO0062757A1 WO 2000062757 A1 WO2000062757 A1 WO 2000062757A1 GB 0001509 W GB0001509 W GB 0001509W WO 0062757 A1 WO0062757 A1 WO 0062757A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
antagonist
applicator
opioid
solution
Prior art date
Application number
PCT/GB2000/001509
Other languages
English (en)
Inventor
David Keith Davies
David Haslam
Original Assignee
Britannia Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Limited filed Critical Britannia Pharmaceuticals Limited
Priority to EP00925468A priority Critical patent/EP1171099A1/fr
Priority to JP2000611894A priority patent/JP2002541921A/ja
Priority to AU44193/00A priority patent/AU4419300A/en
Publication of WO2000062757A1 publication Critical patent/WO2000062757A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated

Definitions

  • compositions for application by spray in the reversal of opioid depression More particularly, compositions are provided for buccal or nasal administration for treatment of patients suffering from opioid over-dosage.
  • Addicts of opioid drugs such as heroin sometimes suffer respiratory failure as a result of administration of an excessive dose of the opioid drug.
  • opioid antagonists may be given to reverse severe opioid respiratory depression, the standard method of adj-ninistration is by intravenous injection, which is difficult for a medically unskilled person to carry out successfully, particularly in the stress of an emergency situation.
  • the present invention seeks to provide systems of administering an opioid antagonist which can be carried out by an unskilled person, rapidly and with a good chance of successfully reviving a patient suffering from opioid over-dosage.
  • a spray applicator having a solution of an opioid antagonist selected from naloxone and/or naltrexone contained in a reservoir therein, the applicator being capable of delivering single or multiple doses of an efficacious amount of said antagonist from the reservoir and the applicator comprising a projecting delivery portion shaped and dimensioned for introduction into the nose or mouth of a patient.
  • compositions for oral or nasal adrninistration comprising an opioid antagonist, the composition being in finely-divided solid form and comprising a water- susceptible solid carrier and the opioid antagonist.
  • the spray applicator may be designed for dispensing the solution into the mouth, e.g. sub-lingually, and be provided with a projecting delivery portion for this purpose.
  • the applicator has a delivery portion which is shaped and dimensioned for introduction into a nostril so that the dose is sprayed directly into the nasal passages.
  • a device which has such a projecting delivery portion can also, if appropriate, be applied directly into the mouth.
  • Suitable spray applicators are preferably single trip devices, and normally incorporate a pump or syringe action for forcing an amount of the solution of the opioid antagonist out of a nozzle.
  • the pharmaceutical composition in powder form, it is preferably adn ⁇ iistered nasally.
  • the composition is packaged via a dispenser having a projecting portion for introduction into a nostril.
  • a propellant is employed for generating an aerosol of the powdered pharmaceutical in a stream of gas.
  • the dispenser will generally include means for metering doses of the composition dispensed into the patient's nasal passages.
  • a preferred opioid antagonist for use in the compositions of this invention is naloxone, which is:-
  • naltrexone Another example of an opioid antagonist is naltrexone, which is:-
  • naloxone is used as a sprayable liquid composition and naltrexone is preferably used in the form of a powdered, solid composition, usually for nasal administration.
  • the antagonist is in the form of a liquid composition
  • it may be a solution in a pharmaceutically acceptable carrier or co-solvent such as water or an alcohol, such as ethanoL e.g. giving an aqueous solution containing about 5% of ethanol.
  • a pharmaceutically acceptable carrier or co-solvent such as water or an alcohol, such as ethanoL e.g. giving an aqueous solution containing about 5% of ethanol.
  • Naloxone and naltrexone are both freely soluble in water and aqueous alcohol when in the form of a salt, such as a hydrochloride.
  • the opioid antagonist may be dissolved in dilute saline solution, e.g. approximately isotonic salt solution. A concentration of about 0.9 weight/volume NaCl in purified water is suitable.
  • the composition may include a buffering agent to maintain the opioid in solution in the salt form, e.g.
  • a phosphate buffer such as sodium hydrogen phosphate to maintain the solution at a slightly acid pH.
  • a solution of the antagonist usually in the form of the hydrochloride, at a concentration of from about 0.5 to 5% by weight, preferably about 1 to 2%, may be employed for nasal or buccal administration.
  • the liquid composition may be packaged in a metered dosage spray dispenser, using a pump or propellant. Suitable dosage units are in the range of 0.2 to 5 mg, preferably 0.2 to 2 mg, especially 0.4 to 1.6 mg.
  • the shot volume could vary between 20 ⁇ l and lOO ⁇ l, with the dose per shot preferably varying between 200 and 1200 ⁇ g.
  • the antagonist is mixed with one or more solid, powdered carriers.
  • Suitable carriers include saccharides such as sorbitol, mannitol, lactose, fructose, glucose and sucrose.
  • Other carriers include water-soluble or swellable polymers such as cellulose derivatives, for example, hydroxypropyl methyl cellulose and carboxymethyl cellulose.
  • a solid salt of the antagonist, e.g. the hydrochloride maybe mixed with a carrier, or coated with the carrier or with a third material such as a hydrophilic polymer.
  • Solid, powdered formulations generally are dispensed at a total shot weight of about 20mg, giving a naloxone dose of 400 ⁇ g per shot.
  • Typical total shot weights may vary between about 10 mg and 30mg and the naloxone dose per shot may be between about 200 and 1200 ⁇ g.
  • the solid, powdered composition containing the opioid antagonist may be packaged in a dispenser with a suitable propellant, such as HFC- 134a or HFC-227.
  • a valve may be provided, which is adapted to dispense a dosage unit of the antagonist of about 0.2 to 5 mg, e.g. 0.4 to 2mg preferably 0.4 to 1.2mg.
  • an anti-oxidant such as ascorbic acid or citric acid in the powdered formulation.
  • the invention is illustrated by the following Examples of pharmaceutical compositions suitable for use in dispensing the opioid antagonist and by the accompanying drawing and description of one form of spray applicator suitable for dispensing the liquid composition.
  • Sprayable aqueous liquid composition for a nasal applicator Sprayable aqueous liquid composition for a nasal applicator.
  • Naloxone hydrochloride was dissolved in a solution of purified water to form a solution containing 0.8% weight/volume of the naloxone.
  • Benzalkonium chloride was added to the hydrochloride solution in an amount of 0.025% weight/volume as a preservative.
  • the solution may be buffered to a pH of about 6.5 using a phosphate buffer (sodium or potassium hydrogen phosphate).
  • the solution was packaged into a dispenser as shown in the accompanying drawing, giving a shot volume of 50 ⁇ l (micro litre) which is equivalent to a unit dose of 400 ⁇ g (microgram) per shot.
  • Powdered solid naloxone hydrochloride was mixed with powdered dextrose or lactose in an amount of from 2% weight/volume naloxone HC1 and 98% weight/volume of the finely powdered sugar.
  • the resulting mixture may be subsequently coated with a vinyl pyrollidone to form a free-flowing powder in which the opioid antagonist is present in a concentration of 2% by weight.
  • the powdered composition was packaged in a dispenser as described in WO 99/27920.
  • Naloxone HC1 was dissolved in water with mannitol or lactose in a weight ratio of 2:98. The resulting solution was spray dried or freeze dried to form a fine powder containing 2% of naloxone HC1.
  • the powdered product could be packaged in an aerosol can with a low boiling propellant fitted with a metering valve or in a dispenser as described in WO 99/27920.
  • the accompanying drawing is a perspective view of an applicator suitable for dispensing liquid solutions of the opioid antagonist.
  • Figure la is a perspective view of a cover cap and Figure 2 is a perspective view of the reservoir 2 and piston 3.
  • the applicator comprises a body part 4 moulded from a flexible plastics material and having a projecting part 5 suitably sized for insertion into a nostril.
  • the projecting part 5 has an internal tube 6 (shown in broken lines in Figure 1), which extends from the tip 7 to approximately the junction between part 5 and the main body part 8. At its distal end, tube 6 is joined to the inside of the projecting part 5, e.g. by fo ⁇ riing part of an integral moulding, and communicates with a discharge orifice 9.
  • a solution of the drug to be dispensed is contained in reservoir 2 which is preferably made from transparent plastic or glass so that it can be seen by inspection if it contains any drug.
  • the solution may be coloured with a pharmaceutically acceptable dye.
  • Piston 3 is made from flexible plastics material (e.g. polythene) and carries a solid piston rod 10 which is formed with a passage 11. Passage 11 communicates with the interior of the reservoir and terminates in a cross bore 12.
  • the assembly consisting of the reservoir 2 and piston 3 and piston rod 10 are fitted into the body 4 of the applicator by introducing the rod 10 into the tube 6.
  • Rod 10 is a free fit into the part of the tube 6 nearest to the part 8 but is a tighter fit into the distal end of the tube.
  • the device works as follows. With the part 5 in the patient's nostril, pressure is applied to the free end of the reservoir, e.g.
  • Tube 6 may be tapered slightly towards the orifice so that higher pressure can be developed within its distal end. It will be appreciated that by shaping the projecting part 5 as a tapering fit in the nostril, a major amount of the composition is retained in the nasal passages.
  • Figure la shows a cap 20 for fitting over the part 5 and n.amtaj.ning it clean prior to use.
  • Cap 20 may be a snap fit onto the base of the projecting part 5 and incorporates a shroud 21 which seals onto the distal end of the part 5.
  • compositions of the invention have the advantage that they can be administered by a first-kettle or person having no medical training, such as a friend or neighbour of an addict.
  • a single dose of the antagonist can readily be sprayed into the nose or mouth of an addict who is having difficulty breathing, while undertaking standard resuscitation procedures. If the patient does not respond to the initial dose, further doses of the antagonist can be given until reversal of the opioid depression is apparent.
  • An advantage is that treatment can be given quickly and effectively without the need for the first-aider to find a blood vessel and give an intravenous injection.
  • Another advantage of the applicators of the invention is that they cannot be misused to give injections of other drugs and are thus more likely to be retained and used for their intended purpose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Mechanical Engineering (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un applicateur pulvérisateur destiné à l'administration d'un antagoniste opioïde choisi entre la naloxone et/ou la naltrexone. L'applicateur de l'invention est capable de distribuer une dose unique ou de multiples doses de l'antagoniste via une partie de distribution saillante dont la forme ou les dimensions lui permettent d'être introduite dans le nez ou la bouche. L'invention se rapporte également à une composition pharmaceutique à administration nasale ou orale comprenant un antagoniste opioïde tel que la naloxone et/ou la naltrexone, ainsi qu'un excipient solide sensible à l'eau mélangé à l'antagoniste opioïde.
PCT/GB2000/001509 1999-04-19 2000-04-18 Composition contenant des antagonistes opioides et atomiseur WO2000062757A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00925468A EP1171099A1 (fr) 1999-04-19 2000-04-18 Composition contenant des antagonistes opioides et atomiseur
JP2000611894A JP2002541921A (ja) 1999-04-19 2000-04-18 オピオイド拮抗物質用スプレイディスペンサ
AU44193/00A AU4419300A (en) 1999-04-19 2000-04-18 Composition containing opioid antagonists and spray dispenser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9908921.1 1999-04-19
GBGB9908921.1A GB9908921D0 (en) 1999-04-19 1999-04-19 Spray dispenser for opiod antagonists

Publications (1)

Publication Number Publication Date
WO2000062757A1 true WO2000062757A1 (fr) 2000-10-26

Family

ID=10851820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001509 WO2000062757A1 (fr) 1999-04-19 2000-04-18 Composition contenant des antagonistes opioides et atomiseur

Country Status (5)

Country Link
EP (1) EP1171099A1 (fr)
JP (1) JP2002541921A (fr)
AU (1) AU4419300A (fr)
GB (2) GB9908921D0 (fr)
WO (1) WO2000062757A1 (fr)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043428A2 (fr) * 2002-08-29 2004-05-27 Novadel Pharma Inc. Capsule ou vaporisateur buccal, polaire et non polaire contenant des medicaments servant a traiter la douleur
US6977070B2 (en) 1997-10-01 2005-12-20 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6998110B2 (en) 1997-10-01 2006-02-14 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule
ITFI20100113A1 (it) * 2010-05-21 2011-11-22 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
EP2289492A3 (fr) * 2002-03-14 2011-12-21 Euro-Celtique S.A. Compositions de clorhydrate de naltrexone
WO2012156317A2 (fr) 2011-05-13 2012-11-22 Euro-Celtique S.A. Formes dosifiées pharmaceutiques intranasales comprenant de la naloxone
CN1726915B (zh) * 2004-07-27 2013-04-24 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔给药系统或组合物及其制备方法
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9078816B2 (en) 1997-10-01 2015-07-14 Suda Ltd. Buccal, polar and non-polar spray containing ondansetron
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
WO2015136373A1 (fr) 2014-03-14 2015-09-17 Lightlake Therapeutics Inc. Produits de médicament nasal et leurs méthodes d'utilisation
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
WO2016007729A1 (fr) * 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Produits médicamenteux co-conditionnés
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US9468747B2 (en) 2014-03-14 2016-10-18 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US9633575B2 (en) 2012-06-06 2017-04-25 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US20180092839A1 (en) * 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
WO2018075979A1 (fr) * 2016-10-21 2018-04-26 Somniferum Labs LLC Compositions, méthodes et kits pour l'administration par inhalation sûre d'opioïdes ciblés pour le traitement de la douleur et de la dépendance
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US10238647B2 (en) 2003-04-29 2019-03-26 Nalpropion Pharmaceuticals, Inc. Compositions for affecting weight loss
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
WO2020198327A1 (fr) * 2019-03-26 2020-10-01 Pocket Naloxone Corp. Dispositifs et procédés d'administration de compositions pharmaceutiques
US20210196625A1 (en) * 2014-07-08 2021-07-01 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11191934B2 (en) 2019-03-26 2021-12-07 Pocket Naloxone Corp. Devices and methods for delivery of pharmaceutical compositions
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
US11324741B2 (en) 2008-05-30 2022-05-10 Nalpropion Pharmaceuticals Llc Methods for treating visceral fat conditions
US11737980B2 (en) 2020-05-18 2023-08-29 Orexo Ab Pharmaceutical composition for drug delivery
US11957647B2 (en) 2021-11-25 2024-04-16 Orexo Ab Pharmaceutical composition comprising adrenaline

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484672B2 (en) * 2019-10-01 2022-11-01 Shareef J. Biltagi Opioid overdose treatment assembly

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
EP0352025A2 (fr) * 1988-07-22 1990-01-24 Baker Cummins Pharmaceuticals, Inc. Utilisation de nalméfène pour le traitement de la rhinite allergique
WO1993015737A1 (fr) * 1992-02-05 1993-08-19 Danbiosyst Uk Limited Compositions pour l'administration par voie nasale contenant des metabolites polaires d'analgesiques opioïdes
WO1998034595A1 (fr) * 1997-02-05 1998-08-13 Jago Research Ag Formulations medicales pour aerosols
WO1999027920A2 (fr) * 1997-12-03 1999-06-10 Britannia Pharmaceuticals Limited Ameliorations apportees a des medicaments pour traiter l'asthme

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501717A (ja) * 1985-10-29 1988-07-14 ベーカー・カミンス・デルマトロジカルス・インコーポレーテッド 抗原誘発性アレルギ−反応を阻止するための方法および組成物
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US5958379A (en) * 1994-09-30 1999-09-28 Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Producte Mbh Pharmaceutical composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
EP0352025A2 (fr) * 1988-07-22 1990-01-24 Baker Cummins Pharmaceuticals, Inc. Utilisation de nalméfène pour le traitement de la rhinite allergique
WO1993015737A1 (fr) * 1992-02-05 1993-08-19 Danbiosyst Uk Limited Compositions pour l'administration par voie nasale contenant des metabolites polaires d'analgesiques opioïdes
WO1998034595A1 (fr) * 1997-02-05 1998-08-13 Jago Research Ag Formulations medicales pour aerosols
WO1999027920A2 (fr) * 1997-12-03 1999-06-10 Britannia Pharmaceuticals Limited Ameliorations apportees a des medicaments pour traiter l'asthme

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969508B2 (en) 1997-10-01 2005-11-29 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6977070B2 (en) 1997-10-01 2005-12-20 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6998110B2 (en) 1997-10-01 2006-02-14 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule
US9078816B2 (en) 1997-10-01 2015-07-14 Suda Ltd. Buccal, polar and non-polar spray containing ondansetron
EP2289492A3 (fr) * 2002-03-14 2011-12-21 Euro-Celtique S.A. Compositions de clorhydrate de naltrexone
WO2004043428A3 (fr) * 2002-08-29 2004-10-21 Novadel Pharma Inc Capsule ou vaporisateur buccal, polaire et non polaire contenant des medicaments servant a traiter la douleur
JP2006505611A (ja) * 2002-08-29 2006-02-16 ノヴァデル ファーマ インコーポレイテッド 疼痛治療用薬剤を含有する、口腔の、極性及び非極性スプレー又はカプセル
WO2004043428A2 (fr) * 2002-08-29 2004-05-27 Novadel Pharma Inc. Capsule ou vaporisateur buccal, polaire et non polaire contenant des medicaments servant a traiter la douleur
US10238647B2 (en) 2003-04-29 2019-03-26 Nalpropion Pharmaceuticals, Inc. Compositions for affecting weight loss
CN1726915B (zh) * 2004-07-27 2013-04-24 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔给药系统或组合物及其制备方法
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US9107837B2 (en) 2006-06-05 2015-08-18 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US11324741B2 (en) 2008-05-30 2022-05-10 Nalpropion Pharmaceuticals Llc Methods for treating visceral fat conditions
US10322121B2 (en) 2010-01-11 2019-06-18 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
ITFI20100113A1 (it) * 2010-05-21 2011-11-22 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
WO2011144746A2 (fr) * 2010-05-21 2011-11-24 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Spray nasal liquide contenant du naltrexone à faible dose
WO2011144746A3 (fr) * 2010-05-21 2012-02-02 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Spray nasal liquide contenant du naltrexone à faible dose
RU2552786C2 (ru) * 2010-05-21 2015-06-10 Л.Мольтени Энд К.Дей Фрателли Алитти Сочиета' Ди Эсерчицио С.П.А. Жидкий назальный спрей, содержащий налтрексон в низкой дозе
CN102905689A (zh) * 2010-05-21 2013-01-30 L.莫尔特尼及阿利蒂兄弟联合股份公司 包含低剂量纳曲酮的液体鼻喷雾
WO2012156317A2 (fr) 2011-05-13 2012-11-22 Euro-Celtique S.A. Formes dosifiées pharmaceutiques intranasales comprenant de la naloxone
KR20140007482A (ko) * 2011-05-13 2014-01-17 유로-셀티큐 에스.에이. 날록손을 포함하는 비강내 제약 투여 형태
US11020343B2 (en) 2011-05-13 2021-06-01 Harm Reduction Therapeutics, Inc. Intranasal pharmaceutical dosage forms comprising naloxone
EP2706982B2 (fr) † 2011-05-13 2021-03-10 Euro-Celtique S.A. Formes dosifiées pharmaceutiques intranasales comprenant de la naloxone
CN107260672A (zh) * 2011-05-13 2017-10-20 欧洲凯尔特公司 包含纳洛酮的鼻内药物剂型
AT16553U1 (de) * 2011-05-13 2020-01-15 Euro Celtique Sa Intranasale pharmazeutische Darreichungsformen umfassend Naloxon
AU2012257785B2 (en) * 2011-05-13 2016-04-14 Euro-Celtique S.A. Intranasal pharmaceutical dosage forms comprising naloxone
TWI486161B (zh) * 2011-05-13 2015-06-01 Euro Celtique Sa 含那若松（ｎａｌｏｘｏｎｅ）的鼻內藥物劑型
US20150018379A1 (en) * 2011-05-13 2015-01-15 Euro-Celtique S.A. Intranasal Pharmaceutical Dosage Forms Comprising Naloxone
US11806428B2 (en) 2011-05-13 2023-11-07 Harm Reduction Therapeutics, Inc. Intranasal pharmaceutical dosage forms comprising naloxone
WO2012156317A3 (fr) * 2011-05-13 2013-05-10 Euro-Celtique S.A. Formes dosifiées pharmaceutiques intranasales comprenant de la naloxone
KR101698182B1 (ko) 2011-05-13 2017-01-19 유로-셀티큐 에스.에이. 날록손을 포함하는 비강내 제약 투여 형태
KR20170010078A (ko) * 2011-05-13 2017-01-25 유로-셀티큐 에스.에이. 날록손을 포함하는 비강내 제약 투여 형태
KR101873174B1 (ko) * 2011-05-13 2018-06-29 유로-셀티큐 에스.에이. 날록손을 포함하는 비강내 제약 투여 형태
RU2657441C1 (ru) * 2011-05-13 2018-06-13 Эро-Селтик С.А. Интраназальные фармацевтические дозированные формы, содержащие налоксон
EP3320893A1 (fr) * 2011-05-13 2018-05-16 Euro-Celtique S.A. Formes dosifiées pharmaceutiques intranasales comprenant de la naloxone
EP2706982B1 (fr) 2011-05-13 2018-01-03 Euro-Celtique S.A. Formes dosifiées pharmaceutiques intranasales comprenant de la naloxone
AU2016204880B2 (en) * 2011-05-13 2017-11-23 Euro-Celtique S.A. Intranasal pharmaceutical dosage forms comprising naloxone
US10403170B2 (en) 2012-06-06 2019-09-03 Nalpropion Pharmaceuticals, Inc. Methods of treating overweight and obesity
US9633575B2 (en) 2012-06-06 2017-04-25 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US9289425B2 (en) 2013-12-20 2016-03-22 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9468747B2 (en) 2014-03-14 2016-10-18 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
EP3777838A1 (fr) 2014-03-14 2021-02-17 Opiant Pharmaceuticals, Inc. Produits de médicament nasal et leurs procédés d'utilisation
US9775838B2 (en) 2014-03-14 2017-10-03 Adapt Pharma Limited Nasal drug products and methods of their use
US9707226B2 (en) 2014-03-14 2017-07-18 Adapt Pharma Limited Nasal drug products and methods of their use
US9629965B2 (en) 2014-03-14 2017-04-25 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
GB2538682A (en) * 2014-03-14 2016-11-23 Opiant Pharmaceuticals Inc Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
GB2538682B (en) * 2014-03-14 2017-12-13 Opiant Pharmaceuticals Inc Nasal drug products and methods of their use
ES2631504R1 (es) * 2014-03-14 2017-12-11 Opiant Pharmaceuticals, Inc. Medicamentos de administración nasal y métodos para su uso
US9211253B2 (en) 2014-03-14 2015-12-15 Lightlake Therapeutics Inc. Nasal drug products and methods of their use
WO2015136373A1 (fr) 2014-03-14 2015-09-17 Lightlake Therapeutics Inc. Produits de médicament nasal et leurs méthodes d'utilisation
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11628139B2 (en) * 2014-07-08 2023-04-18 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11617713B2 (en) * 2014-07-08 2023-04-04 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11975096B2 (en) 2014-07-08 2024-05-07 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US20210196625A1 (en) * 2014-07-08 2021-07-01 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US20210353533A1 (en) * 2014-07-08 2021-11-18 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016007729A1 (fr) * 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Produits médicamenteux co-conditionnés
US20180092839A1 (en) * 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
WO2018075979A1 (fr) * 2016-10-21 2018-04-26 Somniferum Labs LLC Compositions, méthodes et kits pour l'administration par inhalation sûre d'opioïdes ciblés pour le traitement de la douleur et de la dépendance
US11191934B2 (en) 2019-03-26 2021-12-07 Pocket Naloxone Corp. Devices and methods for delivery of pharmaceutical compositions
WO2020198327A1 (fr) * 2019-03-26 2020-10-01 Pocket Naloxone Corp. Dispositifs et procédés d'administration de compositions pharmaceutiques
US10898480B1 (en) 2019-07-09 2021-01-26 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US11883392B2 (en) 2019-07-09 2024-01-30 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US11737980B2 (en) 2020-05-18 2023-08-29 Orexo Ab Pharmaceutical composition for drug delivery
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
US11957647B2 (en) 2021-11-25 2024-04-16 Orexo Ab Pharmaceutical composition comprising adrenaline

Also Published As

Publication number Publication date
EP1171099A1 (fr) 2002-01-16
GB0009622D0 (en) 2000-06-07
JP2002541921A (ja) 2002-12-10
GB2349818A (en) 2000-11-15
AU4419300A (en) 2000-11-02
GB9908921D0 (en) 1999-06-16

Similar Documents

Publication Publication Date Title
WO2000062757A1 (fr) Composition contenant des antagonistes opioides et atomiseur
AU714303B2 (en) Formulation for intranasal administration
AU737506B2 (en) Aqueous-based pharmaceutical composition
JP5599961B2 (ja) 薬学的組成物
US20030077300A1 (en) System and method for intranasal administration of opioids
US20210077382A1 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
US20180092839A1 (en) Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
KR20090005180A (ko) 스프레이용 겔 타입 피부/점막-부착형 제제 및 이를 이용한투여 시스템
RU2767062C2 (ru) Составы, устройства и способы для лечения алкогольной зависимости
JP2002534331A (ja) 分量および送達システム
CA2480123C (fr) Formulations de support liquides a teneur en eau elevee
KR20210131996A (ko) 과다복용 및 보상-기반 장애의 치료를 위한 조성물, 장치 및 방법
WO2021044357A1 (fr) Formulation d'apomorphine
Raal et al. Farmaatsiaterminoloogia ja Euroopa farmakopöa

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 611894

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000925468

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000925468

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09959048

Country of ref document: US

WWR Wipo information: refused in national office

Ref document number: 2000925468

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000925468

Country of ref document: EP